Traditional regulatory frameworks are built on a simple assumption: a product is designed, tested, approved, and frozen. Whether it is a pharmaceutical compound or a hardware-based medical device, the item entering the market is identical to the one evaluated by regulators.
Artificial intelligence shatters this paradigm. Machine learning models are inherently dynamic; they derive their value from their ability to learn, adapt, and update based on new data. When we apply a "build-and-freeze" regulatory model to AI, we create a fundamental mismatch that either compromises safety or paralyzes innovation.
To unlock the potential of continuous learning systems, researchers and policymakers are shifting the core philosophy of regulation: moving away from evaluating a static software artifact and toward governing a continuous lifecycle.
The Static-Dynamic Mismatch
Why can't we simply freeze an AI model after it passes initial clinical or technical validation? The answer lies in the fluid nature of real-world environments.
When a frozen model is deployed, it immediately begins to age. As Holger Fröhlich et al. observe in From hype to reality: data science enabling personalized medicine, traditional medical software regulation relies on a static model that is fundamentally incompatible with machine learning systems, which require continuous updates to maintain or improve performance over time. If a model cannot update, it falls victim to dataset shift—changes in patient demographics, new medical equipment, or evolving clinical practices. As a result, a pre-market snapshot fails to account for post-market algorithmic drift or performance degradation (Michael Da Silva et al., Regulating the Safety of Health-Related Artificial Intelligence).
Traditional Paradigm:
[Design] ──> [Rigorous Test] ──> [Freeze Code] ──> [Deploy Permanently]
└─> Risk: Algorithmic Drift
Continuous Lifecycle Paradigm:
[Design] ──> [Approve Learning Logic] ──> [Deploy] ──> [Monitor & Retrain] ──┐
▲ │
└───────────────────────────┘
However, under current legal frameworks, updating a model to maintain its robustness can technically invalidate its original regulatory clearance (Karim Lekadir et al., FUTURE-AI: international consensus guideline for trustworthy and deployable artificial intelligence in healthcare). This creates a punitive choice for developers: incur the massive cost and delay of full re-certification for every incremental adjustment, or leave an outdated, degrading model in production.
The data shows that this friction has severe consequences. Siwen Zhang et al. note in A decade of review in global regulation and research of artificial intelligence medical devices (2015–2025) that high regulatory costs and lengthy re-certification timelines have forced approximately 78% of manufacturers to suspend algorithm iterations. This "regulatory-induced model stagnation" creates a translation gap where evidence-based, adaptive software is trapped in legal limbo (Inez Myin‐Germeys et al., From progress to paralysis: bridging the translation gap in digital mental health care?).
Regulating the Trajectory, Not the Weights
To resolve this friction, the unit of regulatory evaluation must change. Instead of certifying a specific set of static model weights, frameworks are evolving to certify the process and the boundaries of learning.
An intuitive framing for this shift is proposed by Edward Raff et al. in Dr. AI, Where Did You Get Your Degree?. Instead of regulating AI as a static medical device, the authors suggest treating it like a "medical provider" (a doctor). Regulators do not re-evaluate a human doctor's brain before every surgery; instead, they accredit the training institution, verify the data collection methods, and continuously monitor clinical outcomes.
Mechanistically, this is operationalized through Predetermined Change Control Plans (PCCPs). Under a PCCP framework, manufacturers specify the types of modifications and updates an AI model will undergo before initial deployment (Siwen Zhang et al.).
By approving the underlying learning logic and modification path rather than a static software version, regulators clear a pre-authorized "learning trajectory" (Bouchra Derraz et al., New regulatory thinking is needed for AI-based personalised drug and cell therapies in precision oncology). This allows the model to learn and update from new data post-deployment without requiring a full re-submission, provided the updates remain within the predefined boundaries approved by the total product lifecycle scope (E. Hope Weissler et al., The role of machine learning in clinical research: transforming the future of evidence generation).
Continuous Stewardship and MLOps
Approving a learning trajectory shifts the burden of safety from pre-market gatekeeping to post-market surveillance. For this to work safely, the system must rely on automated quality control and active algorithmic stewardship.
As Luis Oala et al. argue in Machine Learning for Health: Algorithm Auditing & Quality Control, effective quality control cannot be a single pre-deployment check; it must be a continuous lifecycle approach integrated into the planning, development, and post-deployment phases. This ongoing maintenance—termed "algorithmic stewardship" by Lin Shen et al. in The Clinician's Guide to the Machine Learning Galaxy—ensures that deployed models are iteratively updated and audited to account for real-world environmental shifts.
Continuous Retraining Loop (MLOps)
┌────────────────────────────────────────────────────────┐
│ │
▼ │
[Deploy Model] ──> [Stream Real-World Data] ──> [Audit Performance]
│
▼ (If Drift Detected)
[Retrain & Validate]
Practically, this requires an MLOps-based architecture. Bhumika Rawate demonstrates in Revolutionizing Digital Healthcare: An AI-Based Symptom Prediction and Treatment Advisory System how an MLOps paradigm facilitates continuous integration, real-time monitoring, and automated retraining. This architecture prevents a system from becoming a static, outdated tool, ensuring it evolves safely alongside new data distributions.
To mitigate the risks of live updates, regulators can deploy "dynamic regulatory sandboxing" (Michael Da Silva et al.). This provides a isolated, controlled environment where adaptive models can ingest real-world data and update their logic while regulators monitor performance changes in real-time before pushing the updates to production.
The Co-Evolution of Law and Code
The challenge of continuous regulation is not confined to healthcare; it extends to the fluid nature of law itself. Just as AI models experience dataset shift, automated compliance systems face "regulatory shift."
Jivitesh Jain et al. point out in From Complexity to Clarity: AI/NLP's Role in Regulatory Compliance that most automated compliance systems are built on static taxonomies. When legal frameworks are amended or new policies are enacted, these models suffer from knowledge obsolescence. As Tom Zick emphasizes in Comparing Apples to Oranges: A Taxonomy for Navigating the Global Landscape of AI Regulation, the rapid evolution of global AI governance means that any static analysis or taxonomy will quickly become outdated.
Ultimately, regulation must be treated not as a fixed set of rules, but as an active scientific discipline. Jochen K. Lennerz et al. introduce the concept of Regulatory Science in A unifying force for the realization of medical AI, defining it as the systematic study and improvement of the standards used to validate safety and efficacy. By treating regulatory evaluation as a dynamic field of study, the frameworks governing AI can co-evolve alongside the adaptive technologies they are meant to oversee.
Key Foundational Work
Dr. AI, Where Did You Get Your Degree? (2018) — contributed 3 concept elements to this direction.
From hype to reality: data science enabling personalized medicine (2018) — contributed 3 concept elements to this direction.
Approval policies for modifications to Machine Learning-Based Software as a Medical Device: A study of bio-creep (2019) — contributed 1 concept elements to this direction.